The abstract is read at the publisher; the summary is JClub's.
Pancreatic adenosquamous carcinoma shows subtype-specific spatial transcriptomic organization, with immune infiltrates closest to squamous regions and farthest from glandular regions.
- Why it matters: ASQ is rare and has poorly defined clinical and molecular features versus conventional pancreatic ductal adenocarcinoma, limiting subtype-tailored treatment strategies.
- What they did: At Johns Hopkins (2013–2023), outcomes and treatment patterns were assessed in 178 ASQ patients, while FoundationCore compared ASQ (n = 244) versus PDAC (n = 29,021) genomics; Visium spatial transcriptomics analyzed resected ASQ (n = 11 from eight patients) versus PDAC (n = 4).
- The result: ASQ had poor outcomes in both resected and advanced disease, shared key genomic drivers with PDAC but showed higher MTAP loss and enrichment of low-frequency immune biomarkers, supporting subtype-specific therapeutic strategies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.